Posted by Michael Wonder on 31 May 2016
Allergan receives FDA approval of Teflaro (ceftaroline fosamil acetate monohydrate) for paediatric patients
31 May 2016 - Teflaro is the first branded IV antibiotic approved for paediatric patients in more than a decade.
Allergan today announced the US FDA has approved the company's supplemental new drug application for Teflaro (ceftaroline fosamil acetate monohydrate), granting new indications for paediatric patients 2 months of age to less than 18 years of age with acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA), and community-acquired bacterial pneumonia caused by Streptococcus pneumoniae and other designated susceptible bacteria.
